Quince Therapeutics, Inc. · NASDAQ:QNCX
Quince Therapeutics — IRulya Therapeutics — Investor Presentation (October 2026)
35 slides from Quince Therapeutics's investor presentation, Oct 20, 2026
Slide 1: Corporate Presentation October 2026
OCTOBER 2026 C O R P O R AT E P R E S E N TAT I O N
Slide 2: Disclaimers
DISCLAIMERS The information in this Presentation has been prepared by IRulya Therapeutics Inc. (formerly Quince Therapeutics, Inc., “IRulya”, and the “company”) and contains information pertaining to the business and operations of the company. The information contained in this Presentation: (a) is p
Slide 3: Investment Highlights
INVESTMENT HIGHLIGHTS Rare disease focused, clinical-staged biotechnology Efficient 505(b)2 development pathway company developing a novel, once-daily, inhaled, disease for lead program (LAM-001), with strong IP modifying rapamycin formulation (LAM-001) across multiple coverage expected to the mid 2
Slide 4: IRulya Pipeline and Anticipated Milestones
IRULYA PIPELINE AND ANTICIPATED MILESTONES ESTIMATED ANTICIPATED LAM-001 2026 2027 2028 US/EU DATA MARKET READOUTS Pulmonary Hypertension- Phase 2B (PH-ILD) Interstitial Lung Disease ~200k 1Q-28 (PH-ILD) Bronchiolitis Obliterans Phase 2 (IIT) ~30k 1Q-27 Syndrome (BOS) Sarcoidosis Associated PH Phase
Slide 5: Limitations of Oral Rapamycin
LIMITATIONS OF ORAL RAPAMYCIN SYSTEMIC EXPOSURE WITH SIGNIFICANT SAFETY RISKS: Oral Rapamune® Key Label Warnings and Precautions: Angioedema, Fluid Accumulation and Impairment of Wound Healing, Hyperlipidemia, Decline in Renal Function, Proteinuria, Latent Viral Infections, Male Infertility, Embryo-
Slide 6: Solution: LAM-001 Designed for Improved Pulmonary Delivery of Rapamycin
SOLUTION: LAM-001 DESIGNED FOR IMPROVED PULMONARY DELIVERY OF RAPAMYCIN TARGETED DELIVERY: Direct lung delivery → higher local exposure versus oral or nebulized formulations IDEAL PHYSICAL CHEMICAL PROPERTIES FOR LUNG DELIVERY: Enhanced lung exposure and potential improved efficacy in pulmonary dise
Slide 7: LAM-001: Inhaled Rapamycin Advantages Over Oral
LAM-001: INHALED RAPAMYCIN ADVANTAGES OVER ORAL LAM-001 vs oral rapamycin: designed to deliver higher drug Phase 1/2 in LAM Patients exposure in lungs where needed for clinical activity with lower systemic exposure where most toxicities arise • Total dose delivered via inhalation = 20x lower (100 µg
Slide 8: LAM-001: Group 3 Pulmonary Hypertension (PH-ILD)
L A M - 0 0 1 : G R O U P 3 P U L M O N A RY H Y P E R T E N S I O N (PH-ILD)
Slide 9: Pulmonary Hypertension (PH-ILD)
PULMONARY HYPERTENSION (PH-ILD) DISEASE: • Rare, progressive disorder characterized by smooth muscle cell proliferation and endothelial cell dysfunction, leading to thickening and narrowing of the pulmonary blood vessels • Group 3 Pulmonary Hypertension due to underlying interstitial lung disease (I
Slide 10: Rapamycin Targets PH Pathology
RAPAMYCIN TARGETS PH PATHOLOGY PH SMOOTH MUSCLE CELLS (HYPOXIA) +Rapamycin Growth Factor R Hypoxia Hypoxia Rapamycin FKBP12 Activated mTOR Inhibited mTOR ↑ mTOR signaling ↓ mTOR signaling ↑ Proliferation ↓ Proliferation Hassoun NEJM 2021 Krymskaya, et. al., FASEB (2011) LAM-001 has been shown to rev
Slide 11: Rapamycin Inhibits mTOR and Reverses PASMC Proliferation
RAPAMYCIN INHIBITS MTOR AND REVERSES PULMONARY ARTERIAL SMOOTH MUSCLE CELL (PASMC) PROLIFERATION1,2 RAPAMYCIN INHIBITS mTOR, WHICH IS ACTIVATED IN PH1 RAPAMYCIN REVERSES PASMC PROLIFERATION2 MCT 3 wk Control Ve + Rapa 3 wk 1 Based on Goncharov, Circulation. 2014 129: 864. 2 Based on Houssaini, Am J
Slide 12: Competitive Landscape: PH-ILD Products and Product Candidates
COMPETITIVE LANDSCAPE PH-ILD PRODUCTS AND PRODUCT CANDIDATES Once-daily Vasodilation Antiproliferative Antifibrotic Company Status dosing MOA MOA MOA LAM-001 IRulya ✓ -- +++ +++ Ph 2 Tyvaso1 United Therapeutics x +++ -- + Launched Yutrepia Liquidia x +++ -- + Treprostinils Launched TPIP Insmed ✓ +++
Slide 13: Phase 2a Trial of LAM-001 in Group 1 PAH and Group 3 PH
PHASE 2a TRIAL OF LAM-001 IN GROUP 1 PAH AND GROUP 3 PH Week 0 Week 24 AARON B. WAXMAN, MD, PhD Principal Investigator 10 patients; Open label 100 µg LAM-001 qd + SOC iCPET1 iCPET1 DESIGN • Open Label; 24 wks; 4 sites; Invasive Cardiopulmonary Exercise Testing (iCPET)1 INCLUSION • >18 yo; WHO Functi
Slide 14: Phase 2a Baseline Characteristics
PHASE 2a BASELINE CHARACTERISTICS PAH PH-ILD Completers All Enrolled Majority of patients on triple background therapy: N per group 5 5 6 10 Female 4 2 2 6 All PH-ILD patients on background treprostinil Male 1 3 4 4 Age (median yr) 63 65 64 65 Patients on stable background therapy prior to ILD enrol
Slide 15: Phase 2a 24 Week Data Summary
PHASE 2a 24 WEEK DATA SUMMARY Evaluable Population PH-ILD Subgroup • Consistent, clinically relevant improvement from baseline Mean | N = 6 Mean | N = 4 observed across multiple endpoints • In addition to SOC therapy in heavily pre-treated population Δ 6MWD (m) +81.3 +67.4 • Data support potential b
Slide 16: Phase 2a Functional Class Endpoint
PHASE 2a FUNCTIONAL CLASS ENDPOINT 100% • All ten patients FC III at baseline of completers • Six of ten improved to FC II by week twelve 1 improved to FC II • Two patients improved to FC I by Week 24 Functional Class Improvement 2 WHO Functional Class Definition* Class I Symptom-free when physicall
Slide 17: Safety Summary Through 24-Weeks
SAFETY SUMMARY THROUGH 24-WEEKS DRUG RELATED AEs • Grade 1 Productive Cough (n = 1) - Resolving • Grade 2 Cough (n = 1) - Not Resolved • Grade 1 Gingivitis (n = 1) - Resolving LAM-001 NO DOSE NO DISCONTINUATIONS NO DRUG- WAS WELL INTERRUPTIONS DUE TO DRUG RELATED SAEs TOLERATED DUE TO AEs AEs = Adve
Slide 18: Phase 2a Efficacy and Safety Summary
PHASE 2a EFFICACY AND SAFETY SUMMARY COMPELLING CLINICAL ACTIVITY PH-ILD patients +67m improvement observed in 6MWD compares favorably to existing therapies1 FAVORABLE TOLERABILITY LAM-001 well tolerated • No dose interruptions due to AE Benefit seen on top of standard of care in heavily • No discon
Slide 19: Phase 2b Trial of LAM-001 in PH-ILD
PHASE 2b TRIAL OF LAM-001 IN PH-ILD Week 0 BLINDED TREATMENT PHASE Week 24 OPEN LABEL EXTENSION Month 18 100 µg LAM-001 qd (n=25) 75 patients 200 µg LAM-001 qd (n=25) TBD LAM-001 qd (n=75) Placebo (n=25) • Placebo-controlled; Double Blind; Randomized 1:1:1; Multi-center (~60 sites); 24 wks; 12 mo op
Slide 20: LAM-001: Bronchiolitis Obliterans (BOS)
LAM-001: BRONCHIOLITIS OBLITERANS (BOS)
Slide 21: Bronchiolitis Obliterans (BOS)
BRONCHIOLITIS OBLITERANS (BOS) DISEASE: • Leading cause of death post lung transplantation (LT)1 • Orphan Drug Designation granted US and Europe • No FDA approved drugs • ~4,000 lung transplants performed annually in US2 Inflammatory and fibrotic cells Estimated Addressable Patient Population2 BOS P
Slide 22: BOS Major Unmet Need
BOS MAJOR UNMET NEED 6.2 YEARS 11% #1 2.5 YEARS Median survival BOS free survival BOS is the leading Median survival (or post lung at 10 yrs2 cause of death post lung re-transplantation) transplantation1 transplantation3 post development of BOS post lung transplantation4 1 ISHLT Factsheet: https://w
Slide 23: FEV1 Is Key Measure of BOS Progression and Survival
FEV1 IS KEY MEASURE OF BOS PROGRESSION AND SURVIVAL PROGRESSION TO ADVANCED BOS IS MEASURED BY FEV1 DECLINE* BOS Gr 0 BOS Gr 1 BOS Gr 2 BOS Gr 3 FEV1 > 80% FEV1 66 - 80% FEV1 51 - 65% FEV1 ≤50% *Baseline = best post-transplant FEV1 Meyer 2014: DOI: 10.1183/09031936.00107514 Baseline Baseline Baselin
Slide 24: Rapamycin Stabilizes Pulmonary Function in Patients with BOS
RAPAMYCIN STABILIZES PULMONARY FUNCTION IN PATIENTS WITH BOS1 Oral rapamycin administered to patients with Mean FEV1 Values Before and After Rapamycin progressive BOS post lung transplant who had not responded to other treatments PRE-RAPAMYCIN POST-RAPAMYCIN Prior to initiation Post introduction of
Slide 25: Phase 2 Trial of LAM-001 in BOS
PHASE 2 TRIAL OF LAM-001 IN BOS Week 0 BLINDED TREATMENT PHASE Week 48 Month 36 OPEN LABEL EXTENSION 100 µg LAM-001 qd 19 patients 100 µg LAM-001 qd Placebo DESIGN • Randomized 1:1, Double Blind, Placebo controlled, 25 mo open-label extension, Investigator-initiated trial INCLUSION • >18 yo; Newly d
Slide 26: LAM-001: Sarcoidosis Associated Pulmonary Hypertension (SAPH)
L A M - 0 0 1 : S A R C O I D O S I S A S S O C I AT E D P U L M O N A RY H Y P E R T E N S I O N ( S A P H )
Slide 27: Sarcoidosis Associated Pulmonary Hypertension (SAPH)
SARCOIDOSIS ASSOCIATED PULMONARY HYPERTENSION (SAPH) DISEASE: • Sarcoidosis is a disease characterized by the growth of abnormal masses of cells called granulomas – Lungs are affected in 90% of cases (pulmonary sarcoidosis) – SAPH: a severe complication that occurs in 15% of cases1 • 55% 5 yr surviv
Slide 28: Clinical Case Study (Rapamycin): Pulmonary Sarcoidosis
CLINICAL CASE STUDY (RAPAMYCIN): PULMONARY SARCOIDOSIS COMPLETE RESPONSE IN SEVERE PULMONARY SARCOIDOSIS Patient PET scans before and after • Patient with severe pulmonary sarcoidosis failed to respond to prednisone, JAKi and Rapamycin (sirolimus) treatment azathioprine, methotrexate, hydroxychloroq
Slide 29: mTOR Inhibition Demonstrates Activity in Cutaneous Sarcoidosis
mTOR INHIBITION DEMONSTRATES ACTIVITY IN CUTANEOUS SARCOIDOSIS Cutaneous Sarcoidosis Skin immune and non-immune cells Activity and Morphology Index upon systemic mTOR inhibition N=3 N=7 mTOR activity in dermal skin cells N=3 N=7 Subjects with Cutaneous Sarcoidosis treated with Oral Rapamycin for 4 m
Slide 30: Phase 2 Trial of LAM-001 in SAPH
PHASE 2 TRIAL OF LAM-001 IN SAPH1 Screening Week 0 BLINDED TREATMENT PHASE Week 24 Week 48 100 µg LAM-001 qd (20 pts) OPEN LABEL EXTENSION 60 patients 200 µg LAM-001 qd (20 pts) LAM-001 qd (60 pts) Placebo (20 pts) DESIGN • Placebo-controlled, double-blind, R1:1:1, 24 wks, up to 50 sites (ww), 6-mo
Slide 31: IP, Financial, & Milestones
IP, FINANCIAL, & MILESTONES ecee
Slide 32: Broad IP Strategy Supporting LAM-001 Exclusivity
BROAD IP STRATEGY SUPPORTING LAM-001 EXCLUSIVITY FDA ORANGE BOOK AFFORDS PROTECTION FOR 3 TYPES OF PATENTS COMPOSITION CLAIMS METHOD CLAIMS 9 US AND 25 INTERNATIONAL MULTIFACETED IP AND Drug Substance (DS) Method of Treatment (MoT) PATENTS ISSUED* – EXPECTED EXCLUSIVITY STRATEGY • Particle size • Us
Slide 33: Well-Capitalized with Funding from Leading Healthcare Investors
M AY 2 0 2 6 F I N A N C I N G OVERSUBSCRIBED \ $115M UPFRONT FINANCING LED BY WELL-CAPITALIZED INCLUDING WITH FUNDING FROM LEADING HEALTHCARE INVESTORS 33
Slide 34: Anticipated Milestones
ANTICIPATED MILESTONES 1Q27 1Q28 4Q28 LAM-001 BOS LAM-001 PH-ILD LAM-001 SAPH Phase 2 Data Phase 2b Data Phase 2 Data 34
Slide 35: Thank You
“IRulyat THANK YOU OCTOBER 2026
IRulya Therapeutics — Investor Presentation (October 2026) on 6ix